Latest Advocacy Group Content

Latest Content

Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

December 5th 2020, 9:07pm

By Ryan McDonald

Article

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival

December 5th 2020, 8:00pm

By Jessica Skarzynski

Article

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

How Cold Weather Affects Patients with Cancer

December 5th 2020, 7:00pm

By Tampa Bay Radiation Oncology

Article

Winter brings added challenges for patients with cancer. Here's what you need to know to take into consideration as the weather gets colder.

CURE®’s 8th Annual MPN Heroes Program Honors ‘Team of Warriors’ Who Have Overcome Challenges in Myeloproliferative Neoplasms

December 5th 2020, 3:00pm

By Ryan McDonald

Article

Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.

Sponsored by Kyowa Kirin: Understanding the Ins and Outs of CTCL

December 5th 2020, 1:00pm

Article

Dr. Yuliya Linhares discusses cutaneous T-cell lymphoma and the role of a multidisciplinary team of specialists in designing and managing care.

Venclexta With Velcade and Dexamethasone May Improve Progression-Free Survival in Relapsed or Refractory Multiple Myeloma

December 4th 2020, 10:00pm

By Darlene Dobkowski, MA

Article

The phase 3 trial found that this treatment improves progression-free survival (PFS) during 18.7 months of follow-up, although patients treated with Venclexta (venetoclax) a had increased mortality rates compared with those treated with placebo.

Faith, Science, and Miracles: A Conversation About CAR-T Cell Therapy with the Whitehead Family

December 4th 2020, 8:00pm

By Jessica Skarzynski

Article

Emily Whitehead was the first child to receive chimeric antigen receptor (CAR)-T cell therapy. Eight years later, she and her parents discuss her ongoing remission from acute lymphoblastic leukemia.

Cancer, Boundaries, Safety and COVID-19 Considerations During the Holidays

December 4th 2020, 5:00pm

By Tamera Anderson-Hanna

Article

Figuring out boundaries and safety in relation to COVID-19 has been an ongoing challenge this year, and with the holidays coming up pressure is mounting. Here is how one cancer survivor considered their boundaries this year.

Friday Frontline: Preliminary Evidence Shows Connection Between Cancer Recurrence and Stress-Related Hormones, Texas Mayor Tests Positive for COVID-19 After Cancer Diagnosis, and More

December 4th 2020, 4:00pm

By Conor Killmurray

Article

From a recently published study showing preliminary connections between elevated levels of stress-related hormones and cancer recurrence, to a Texas mayor receiving a diagnosis of cancer and COVID-19, here’s what’s happening in the cancer landscape this week.

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma

December 4th 2020, 2:00pm

Article

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

x